Dyne Therapeutics (NASDAQ:DYN) Sets New 12-Month Low – Here’s What Happened

Dyne Therapeutics, Inc. (NASDAQ:DYN) reached a new 52-week low on Tuesday . The company traded as low as $11.33 and last traded at $11.50, with a volume of 1605555 shares changing hands. The stock had previously closed at $12.40.

Analysts Set New Price Targets

A number of research firms have weighed in on DYN. HC Wainwright decreased their price objective on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Scotiabank began coverage on Dyne Therapeutics in a report on Friday. They set a “sector outperform” rating and a $50.00 price objective on the stock. Piper Sandler decreased their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Finally, Robert W. Baird began coverage on Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $48.75.

Dyne Therapeutics Trading Down 7.3 %

The firm has a fifty day simple moving average of $15.56 and a 200-day simple moving average of $26.06. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -3.23 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, equities analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now owns 127,078 shares in the company, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the sale, the insider now owns 201,685 shares of the company’s stock, valued at $5,671,382.20. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,387 shares of company stock valued at $142,789. 20.77% of the stock is currently owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $34,000. Point72 DIFC Ltd bought a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $36,000. US Bancorp DE raised its position in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Dyne Therapeutics during the 4th quarter valued at $50,000. Finally, KBC Group NV raised its position in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after acquiring an additional 978 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.